<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">46689</article-id><article-id pub-id-type="doi">10.7554/eLife.46689</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-135320"><name><surname>Hu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-135321"><name><surname>Zhang</surname><given-names>Yong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6664-435X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-76581"><name><surname>Sun</surname><given-names>Xiaolin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-148460"><name><surname>Zhang</surname><given-names>Tongtong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135322"><name><surname>Xu</surname><given-names>Liling</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135323"><name><surname>Xie</surname><given-names>Hengyi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-76582"><name><surname>Li</surname><given-names>Zhanguo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-135112"><name><surname>Liu</surname><given-names>Wanli</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0395-2800</contrib-id><email>liulab@tsinghua.edu.cn</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-135324"><name><surname>Lou</surname><given-names>Jizhong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4031-6125</contrib-id><email>jlou@ibp.ac.cn</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-76578"><name><surname>Chen</surname><given-names>Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5366-7253</contrib-id><email>jackweichen@zju.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Neurobiology and Department of Cardiology of the Second Affiliated Hospital</institution><institution>Zhejiang University School of Medicine</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Key Laboratory of RNA Biology, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics</institution><institution>Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Department of Rheumatology and Immunology, Peking-Tsinghua Center for Life Sciences</institution><institution>Peking University People's Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">MOE Key Laboratory of Protein Sciences, Center for Life Sciences, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, School of Life Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Institute for Immunology</institution><institution>Tsinghua University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Key Laboratory for Biomedical Engineering of Ministry of Education, State Key Laboratory for Modern Optical Instrumentation, College of Biomedical Engineering and Instrument Science, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases</institution><institution>Zhejiang University</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib><contrib contrib-type="editor"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>25</day><month>07</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e46689</elocation-id><history><date date-type="received" iso-8601-date="2019-03-22"><day>22</day><month>03</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-07-25"><day>25</day><month>07</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Hu et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Hu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-46689-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.46689.001</object-id><p>FcγRIIB binding to its ligand suppresses immune cell activation. A single-nucleotide polymorphic (SNP) change, I232T, in the transmembrane (TM) domain of FcγRIIB loses its suppressive function, which is clinically associated with systemic lupus erythematosus (SLE). Previously, we reported that I232T tilts FcγRIIB’s TM domain. In this study, combining with molecular dynamics simulations and single-cell FRET assay, we further reveal that such tilting by I232T unexpectedly bends the FcγRIIB’s ectodomain toward plasma membrane to allosterically impede FcγRIIB’s ligand association. I232T substitution reduces in situ two-dimensional binding affinities and association rates of FcγRIIB to interact with its ligands, IgG1, IgG2 and IgG3 by three to four folds. This allosteric regulation by an SNP provides an intrinsic molecular mechanism for the functional loss of FcγRIIB-I232T in SLE patients.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.46689.002</object-id><title>eLife digest</title><p>Left unchecked the immune system can cause devastating damage to healthy tissue. To prevent this from happening, immune cells have built-in off switches that dampen their activation. One such switch is a protein called FcγRIIB that sits on the outer surface of immune cells and binds to proteins known as antibodies, which are produced as part of the immune response. Its role is to act as a brake on the immune system, and stop it from getting out of control.</p><p>Overactive immune cells can lead to autoimmune diseases such as systemic lupus erythematosus, also known as SLE for short, which causes damage to the skin, joints and other organs. Previous work suggests that SLE is correlated with a specific mutation in the FcγRIIB gene, but it is unclear how the mutation and the disease are connected.</p><p>Proteins are made out of building blocks called amino acids, which have different chemical properties. A swap of one amino acid for another can have big consequences for the structure of a protein. In the case of FcγRIIB, the mutation that correlates with SLE changes an amino acid called isoleucine for another called threonine. Isoleucine does not mix well with water and is commonly found buried in the middle of proteins or inside cell membranes. Threonine, on the other hand, can readily interact with the hydrogen atoms in water and other amino acids.</p><p>Hu, Zhang, Sun et al. used computer simulations and imaged single human cells to find out how the isoleucine to threonine change causes immune cells to become over-activated. The experiments revealed that threonine interacts with a nearby amino acid, putting a kink in the FcγRIIB protein. This kink causes the outer part of the FcγRIIB protein to bend towards the immune cell membrane, stopping it from binding to antibodies, and putting a break on immune cells that have become hyper-activated.</p><p>There is currently no cure for SLE, but understanding its causes could take us a step closer to better management of the disease. Small molecule drug treatments often target the three-dimensional shape of certain proteins, so understanding the effect of mutations at the molecular level could help with the design of new treatments in the future.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>FcγRIIB</kwd><kwd>single-nucleotide polymorphism</kwd><kwd>systemic lupus erythematosus</kwd><kwd>in-situ 2D binding kinetics</kwd><kwd>allosterically conformational change</kwd><kwd>membrane receptor</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012166</institution-id><institution>National Basic Research Program of China</institution></institution-wrap></funding-source><award-id>2015CB910800</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31470900</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31522021</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>11672317</award-id><principal-award-recipient><name><surname>Lou</surname><given-names>Jizhong</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>11772348</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Fundamental Research Funds for the Central Universities</institution></institution-wrap></funding-source><award-id>2015XZZX004-32</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Wei</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A single-nucleotide I232T polymorphic change in FcγRIIB's transmembrane domain bends FcγRIIB's ectodomains toward cell membrane to allosterically hinder FcγRIIB's ligand association, providing novel molecular mechanism for functional loss of FcγRIIB-I232T.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Disorders of immune components could lead to autoimmune diseases. Malfunction of an immune receptor, FcγRIIB, is generally destructive for immune system (<xref ref-type="bibr" rid="bib18">Niederer et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Pincetic et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Smith and Clatworthy, 2010</xref>). FcγRIIB is widely expressed on most types of immune cells including B cells, plasma cells, monocytes, dendritic cells, macrophages, neutrophils, basophils, mast cells and even memory CD8<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib23">Starbeck-Miller et al., 2014</xref>). Among all the immune-receptors for Fc portion of IgG molecules (FcγRs), FcγRIIB is unique due to its suppressive function against immune cell activation. It has been shown that single-nucleotide polymorphisms (SNPs) of the human FcγRIIB gene extensively influence the susceptibility toward autoimmune disorders (<xref ref-type="bibr" rid="bib14">Kyogoku et al., 2002</xref>; <xref ref-type="bibr" rid="bib18">Niederer et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Smith and Clatworthy, 2010</xref>). A T-to-C variant in exon 5 (rs1050501) of FcγRIIB causes the I232T substitution (FcγRIIB-I232T) within the transmembrane (TM) domain and is positively associated with systemic lupus erythematosus (SLE) in the homozygous FcγRIIB-I232T populations as reported in epidemiological studies (<xref ref-type="bibr" rid="bib4">Chu et al., 2004</xref>; <xref ref-type="bibr" rid="bib5">Clatworthy et al., 2007</xref>; <xref ref-type="bibr" rid="bib14">Kyogoku et al., 2002</xref>; <xref ref-type="bibr" rid="bib18">Niederer et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">Siriboonrit et al., 2003</xref>; <xref ref-type="bibr" rid="bib24">Willcocks et al., 2010</xref>). Although a statistical linkage of the homozygous FcγRIIB-I232T polymorphism with SLE is established, comprehensive assessments and mechanistic investigations towards the inter-linkage of FcγRIIB-I232T regarding to the age of syndrome onset, progress, and clinical manifestation of SLE are still lacking. We first address this question in this report.</p><p>Previous biochemical studies revealed that monocytes harboring FcγRIIB-232T (232T) are hyper-activated with augmented FcγRI-triggered phospholipase D activation and calcium signaling (<xref ref-type="bibr" rid="bib9">Floto et al., 2005</xref>). B lymphocytes expressing 232T are of hyperactivity with abnormal elevation of PLCγ2 activation, proliferation and calcium mobilization (<xref ref-type="bibr" rid="bib13">Kono et al., 2005</xref>). 232T-expressing B cells lose the ability to inhibit the oligomerization of B cell receptors (BCRs) upon co-ligation between BCR and FcγRIIB (<xref ref-type="bibr" rid="bib15">Liu et al., 2010</xref>). Recent live-cell imaging studies showed that B cells expressing 232T fail to inhibit the spatial-temporal co-localization of BCR and CD19 within the B cell immunological synapses (<xref ref-type="bibr" rid="bib28">Xu et al., 2014</xref>). Human primary B cells from SLE patients with homozygous FcγRIIB-I232T reveal hyper-activation of PI3K (<xref ref-type="bibr" rid="bib28">Xu et al., 2014</xref>). Thus, it is very likely that FcγRIIB-I232T is the first example that a naturally occurring diseases-associated SNP within the TM domain of a single-pass transmembrane receptor can allosterically suppress the receptor’s ligand recognition and signaling functions. FcγRIIB’s suppressive function is triggered by its ligand engagement, while this function is disrupted by a single amino acid change in the 232th residue from Ile to Thr in FcγRIIB’s TM domain. Two early biochemical studies proposed a model of reduced affinity between 232T and lipid rafts to explain the functional relevance and effect of this natural mutation (<xref ref-type="bibr" rid="bib9">Floto et al., 2005</xref>; <xref ref-type="bibr" rid="bib13">Kono et al., 2005</xref>). A recent study also proposed a different model that I232T mutation enforces the inclination of the TM domain inside the membrane, thereby reducing the lateral mobility and inhibitory functions of FcγRIIB (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>). However, both models assumed that 232T and FcγRIIB-WT (232I) have an equal capability to perceive and bind to their ligands, the IgG’s Fc portion within the antibody-antigen immune complexes. This important but experimentally un-proved pre-requisition in both models is based on the argument that 232T and 232I are identical in the amino acid sequence of their extracellular domains and thus the potential structure of ligand binding site for recognizing the ligands, that is, the IgG’s Fc portions (<xref ref-type="bibr" rid="bib7">Dal Porto et al., 2004</xref>; <xref ref-type="bibr" rid="bib6">D'Ambrosio et al., 1996</xref>). However, to date, there is no direct experimental evidence to validate this pre-requisite assumption. We also address this question in this report.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><p>In this report, we firstly performed systemic examination over the association of FcγRIIB-I232T with clinical manifestations of SLE. We enrolled 711 unrelated Chinese SLE patients with complete clinical documents into this study (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). 688 unrelated healthy Chinese volunteers with matched gender and age were also enrolled as controls (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). We confirm the presence of a strong positive association of the homozygous FcγRIIB-I232T polymorphism with SLE (<italic>χ<sup>2</sup></italic> <italic>= </italic>27.224, p=0.008, odds ratio with 95% confidence interval (CI) = 1.927) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), consistent with the published epidemiological data (<xref ref-type="bibr" rid="bib4">Chu et al., 2004</xref>; <xref ref-type="bibr" rid="bib5">Clatworthy et al., 2007</xref>; <xref ref-type="bibr" rid="bib14">Kyogoku et al., 2002</xref>; <xref ref-type="bibr" rid="bib18">Niederer et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">Siriboonrit et al., 2003</xref>; <xref ref-type="bibr" rid="bib24">Willcocks et al., 2010</xref>). Next, we comprehensively analyzed the clinical data for all 711 SLE patients, including 50 FcγRIIB-I232T homozygotes, 283 FcγRIIB-I232T heterozygotes and 378 FcγRIIB-WT carriers (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). We find that the homozygous FcγRIIB-I232T polymorphism is significantly associated with early disease onset (age at disease onset &lt;37, p=0.002) (<xref ref-type="table" rid="table1">Table 1</xref>). We also observe a significant association of the homozygous FcγRIIB-I232T polymorphism with more severe SLE clinical manifestations since the corresponding SLE patients present significant elevation in the amounts of anti-dsDNA antibodies (p=0.004), anti-nuclear antibodies (p=0.021) and total Immunoglobulin (Ig) (p=0.032) in comparison to patients carrying heterozygous FcγRIIB-I232T polymorphism or FcγRIIB-WT (<xref ref-type="table" rid="table1">Table 1</xref>). Moreover, homozygous FcγRIIB-I232T polymorphism is also significantly associated with the higher SLE disease activity index (SLEDAI) score (p=0.014 for SLEDAI ≥12 vs. p=0.861 for SLEDAI &lt;12) as well as more severe clinical manifestations including arthritis (p=0.008), anemia (p=0.006), leukopenia (p=0.005), complement decrease (p=0.006), hematuria (p=0.004) and leucocyturia (p=0.010) (<xref ref-type="table" rid="table1">Table 1</xref>). A suggestive association is also observed between homozygous FcγRIIB-I232T polymorphism and serositis (p=0.063) (<xref ref-type="table" rid="table1">Table 1</xref>). These clinical association analyses demonstrate that SLE patients homozygous for FcγRIIB-I232T polymorphism are prone to develop more severe clinical manifestations than the patients carrying heterozygous FcγRIIB-I232T polymorphism or FcγRIIB-WT, reinforcing the importance to study the pathogenic mechanism of FcγRIIB-I232T polymorphism since this SNP occurs at a notable frequency in up to 40% (heterozygous polymorphism) humans (<xref ref-type="bibr" rid="bib18">Niederer et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Smith and Clatworthy, 2010</xref>).</p><table-wrap id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.46689.003</object-id><label>Table 1.</label><caption><title>Association analysis between homozygous FcγRIIB-I232T genotype and SLE in subphenotype-control cohorts, adjusting for age and sex</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Genotype frequency</th><th colspan="3">Subphenotype vs. controls</th></tr></thead><tbody><tr><td/><td>Tt+tc (%)/CC (%)</td><td>OR</td><td>95%</td><td><italic>P</italic> value</td></tr><tr><td>Controls</td><td>376+286 (96.2)/26 (3.8)</td><td/><td/><td/></tr><tr><td>Disease Onset, age &lt; 37</td><td>207+150 (92.7)/28 (7.3)</td><td>2.739</td><td>1.456–5.152</td><td>0.002</td></tr><tr><td>Disease Onset, age &gt;= 37</td><td>171+133 (93.3)/22 (6.7)</td><td>1.657</td><td>0.872–3.150</td><td>0.123</td></tr><tr><td>Arthritis = 1</td><td>203+166 (92.5)/30 (7.5)</td><td>2.074</td><td>1.206–3.565</td><td>0.008</td></tr><tr><td>Arthritis = 0</td><td>132+87 (94.8)/12 (5.2)</td><td>1.41</td><td>0.698–2.847</td><td>0.338</td></tr><tr><td>Hematological involvement = 1</td><td>242+185 (93.4)/30 (6.6)</td><td>1.797</td><td>1.048–3.084</td><td>0.033</td></tr><tr><td>Hematological involvement = 0</td><td>90+75 (94.8)/9 (5.2)</td><td>1.369</td><td>0.627–2.988</td><td>0.431</td></tr><tr><td valign="top">Anemia = 1</td><td>126+94 (91.7)/20 (8.3)</td><td valign="top">2.323</td><td valign="top">1.270–4.249</td><td valign="top">0.006</td></tr><tr><td valign="top">Anemia = 0</td><td>153+125 (94.2)/17 (5.8)</td><td valign="top">1.552</td><td valign="top">0.828–2.907</td><td valign="top">0.17</td></tr><tr><td valign="top">Leukopenia = 1</td><td>140+114 (91.7)/23 (8.3)</td><td valign="top">2.294</td><td valign="top">1.284–4.099</td><td valign="top">0.005</td></tr><tr><td valign="top">Leukopenia = 0</td><td>136+107 (94.9)/13 (5.1)</td><td valign="top">1.345</td><td valign="top">0.680–2.663</td><td valign="top">0.394</td></tr><tr><td>dsDNA = 1</td><td>198+151 (92.1)/30 (7.9)</td><td>2.224</td><td>1.293–3.826</td><td>0.004</td></tr><tr><td>dsDNA = 0</td><td>129+94 (94.5)/13 (5.5)</td><td>1.48</td><td>0.747–2.932</td><td>0.261</td></tr><tr><td>ANA = 1</td><td>308+241 (93.4)/39 (6.6)</td><td>1.82</td><td>1.094–3.030</td><td>0.021</td></tr><tr><td>ANA = 0</td><td>25+16 (93.2)/3 (6.8)</td><td>1.893</td><td>0.549–6.526</td><td>0.312</td></tr><tr><td>Total Ig = 1</td><td>131+101 (92.8)/18 (7.2)</td><td>1.969</td><td>1.060–3.66</td><td>0.032</td></tr><tr><td>Total Ig = 0</td><td>120+88 (93.7)/14 (6.3)</td><td>1.706</td><td>0.874–3.328</td><td>0.118</td></tr><tr><td>Complement Decrease = 1</td><td>227+162 (92.4)/32 (7.6)</td><td>2.1</td><td>1.233–3.578</td><td>0.006</td></tr><tr><td>Complement Decrease = 0</td><td>58+54 (95.7)/5 (4.3)</td><td>1.124</td><td>0.423–2.991</td><td>0.814</td></tr><tr><td valign="top">Hematuria = 1</td><td>95+65 (90.9)/16 (9.1)</td><td valign="top">2.634</td><td valign="top">1.370–5.063</td><td valign="top">0.004</td></tr><tr><td valign="top">Hematuria = 0</td><td>180+140 (94.7)/18 (5.3)</td><td valign="top">1.423</td><td valign="top">0.768–2.635</td><td valign="top">0.262</td></tr><tr><td valign="top">Leucocyturia = 1</td><td>64+57 (91.0)/12 (9.0)</td><td valign="top">2.541</td><td valign="top">1.246–5.178</td><td valign="top">0.010</td></tr><tr><td valign="top">Leucocyturia = 0</td><td>196+143 (93.9)/22 (6.1)</td><td valign="top">1.651</td><td valign="top">0.922–2.957</td><td valign="top">0.092</td></tr><tr><td>Serositis = 1</td><td>66+45 (92.5)/9 (7.5)</td><td>2.108</td><td>0.961–4.627</td><td>0.063</td></tr><tr><td>Serositis = 0</td><td>225+174 (94.1)/25 (5.9)</td><td>1.615</td><td>0.919–2.838</td><td>0.096</td></tr><tr><td>SLEDAI &gt;= 12</td><td>20+25 (88.2)/6 (11.8)</td><td>3.327</td><td>1.273–8.696</td><td>0.014</td></tr><tr><td>SLEDAI &lt; 12</td><td>116+93 (95.9)/9 (4.1)</td><td>1.072</td><td>0.493–2.328</td><td>0.861</td></tr></tbody></table></table-wrap><p>Next, we examined whether I232T polymorphic substitution in the TM domain of FcγRIIB allosterically affects ligand recognition. We did this investigation as our previous observation of the inclination of the TM domain by I232T (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>) led us to hypothesize that tilted TM domain of 232T may lead to ectodomain conformational changes to allosterically attenuate ligand binding. We first carried out large-scale molecular dynamics simulations (MDS) with modeled structures of almost full-length human FcγRIIB (either 232I or 232T) imbedded in the lipid bilayer (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). The simulations confirm our previous results with the MDS of the TM domain of FcγRIIB only (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>), that is, I232T polymorphic substitution enforces the inclination of the TM domain (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, right). This inclination might result from the ability of H-bond formation between the side-chain Oγ atom of T232 and the backbone oxygen atom of a neighbor residue V228 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, left). The difference of the TM domain orientation between 232I and 232T induces a distinct conformation on the ecto-membrane proximal region (ecto-TM linker) (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). The membrane buried non-helical region of the linker extends more in 232T than that in 232I. And the length between S218 and P221 peaks at 11 Å for 232T, about 3 Å longer than that for 232I (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This length elongation further results in different conformation of residue P217. The main chain dihedral angle of P217 in 232I displays two populations at 141°±23° and −50°±12°, respectively, but shifts to −40°±45° and −75°±12° in 232T (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). These effects propagate and lead to a striking effect on tilting FcγRIIB’s extracellular domains toward the lipid membrane (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Although the extracellular domains of 232I and 232T, especially their IgG binding sites, do not undergo obvious conformational change (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>), their orientations toward the membrane differ significantly. The ectodomain of 232I maintains more straight-up conformation, whereas that of 232T bends down toward the lipid bilayer (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Statistical analyses show that the ectodomain inclination angle of 232T distributes across 30 ~ 60° with a sharper single-peak at 40° (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In contrast, the angle of 232I distributes much flatter with a favorable probability ranging from 50° to 70° (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The distance of C1 domain to the membrane is shorter for 232T than 232I (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). To check whether these observations result from the thickness of the lipid membrane model, we carried out further simulations using lipids with shorter (14:0/16:1) or longer fatty acid tail (18:0/20:1) (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). The TM helix tilting and S218-P221 prolongation for 232T can be readily observed in these two systems (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B–4C</xref>). These results suggest that I232T substitution may reduce the ligand recognition ability of FcγRIIB via two aspects. First, the tilting orientation of 232T may sterically prevent the accessibility of the IgG’s Fc portion, as significant clashes between docked Fc and the membrane are observed, although FcγRIIB’s Fc binding site is not completely buried into the membrane (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Second, the ectodomain of 232T is less flexible (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) such that the chance for FcγRIIB to associate with the ligand is greatly decreased.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.46689.004</object-id><label>Figure 1.</label><caption><title>MD simulations reveal different conformations of 232I and 232T.</title><p>(<bold>A</bold>) The modeled structures of almost full-length FcγRIIB (232I and 232T, residues A46-I310, shown in gray cartoon) are complexed with IgG Fc (using the complex structure of IgG Fc and FcγRIIB ectodomain, PDB ID: 3WJJ as a reference, shown in color shaded surface) and imbedded in an asymmetric lipid bilayer (lines with atoms colored by element type: P, tan; O, red; N, blue; C, cyan). The helical structures in the vicinity of residue 232 for 232I (green) and 232T (blue) are shown in the insets. (<bold>B</bold>) Probability distributions of the distance between T232 Oγ atom and its nearest backbone O atom from residue V228 (left), and of the tilting angles between TM helix and lipid bilayer (right). The inclination of TM for 232T can be observed clearly. Blue dashed line in the upper inset of the left panel indicates H-bond. (<bold>C</bold>) The representative snapshot comparison of 232I and 232T at the stalk and TM region by superposing the lipid bilayers (left), and the length distribution of S218-P221 backbone in normal direction of lipid bilayer (right). (<bold>D</bold>) Conformational comparison of I212-S220 regions by aligning residues S218 to S220 (left), and the time courses of the dihedral angles (ψ, φ) of residue P217 (right). (<bold>E</bold>) Representative snapshots of 232I and 232T with the inclination angles and C1(Ig-like C2-Type one domain)/bilayer distances, probability distributions of the inclination angle between FcγRIIB ectodomain and lipid bilayer (left), and the distances between C1 domain and lipid bilayer (right).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46689.005</object-id><label>Figure 1—figure supplement 1.</label><caption><title>I232T polymorphic change of FcγRIIB induces the ectodomain recumbent and may impair its binding to Fc portion of antibodies.</title><p>(<bold>A</bold>) The modeled structure of the transmembrane region is highlighted. Residue 232 is the only difference between 232I and 232T. (<bold>B</bold>) The ectodomain of 232I (green) stands straight and is free for Fc binding. (<bold>C</bold>) For FcγRIIB-I232T polymorphic change, although the Fc binding site is still accessible, it occurs the clashes between the Fc and membrane. Therefore, the binding ability of 232T (blue) with Fc may be significantly reduced. The ectodomain in the FcγRIIB/Fc complex structure (PDB code: 3WJJ) is superimposed to that observed by the MD simulation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46689.006</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Conformation differences of ecto-TM linker and its vicinity between 232I (green) and 232T (blue) are obtained by MD simulations.</title><p>(<bold>A</bold>) The conformation of the ecto-TM linker in lipid bilayer (left) or lipids removed (right, the residues number in this region is indicated). (<bold>B</bold>) Conformation differences of I212-S220 region were showed through aligning residues S218 to S220.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46689.007</object-id><label>Figure 1—figure supplement 3.</label><caption><title>IgG-binding sites in both 232I and 232T do not undergo significant structural change.</title><p>(<bold>A</bold>) RMSD time courses of protein backbone atoms in Ig-like C2-type two domain (left panel, colored red on the crystal structure shown in the inset) and IgG binding site (composed mainly with the residues W132, K158, R176 and Y202; right panel and colored red on the crystal structure shown in the inset) for 232I (green) or 232T (blue). No significant change in the domain and the binding site can be observed. (<bold>B</bold>) Structural comparison between crystal structure (gray) and representative snapshots of MD simulations in the 232I (green) or 232T(blue) system.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46689.008</object-id><label>Figure 1—figure supplement 4.</label><caption><title>The length of fatty acid chain and membrane thickness do not alter the effect of I232T polymorphism on the tilting of TM domain.</title><p>(<bold>A</bold>) Schematic of 14:0/16:1, 16:0/18:1 and 18:0/20:1 lipids (upper), and the membrane thickness comparisons with different lengths of lipid fatty acid chain (bottom). MD simulation results of TM helix tilting angle (<bold>B</bold>), and S218-P221 prolongation (<bold>C</bold>) in lipid membranes with different-length lipids and membrane thickness.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig1-figsupp4-v2.tif"/></fig></fig-group><p>We next performed single-cell fluorescence resonance energy transfer (FRET) assay to experimentally validate whether I232T polymorphic change could allosterically bend the FcγRIIB ectodomain toward cell membrane. We fused an mTFP (as FRET donor) at the N-terminal of 232I or 232T ectodomain (mTFP-232I or mTFP-232T) and hypothesized that it should fall in the spatial proximity (~16 ~ 36 Å) for FRET with plasma outer membrane labeled with octadecyl rhodamine B (R18, as FRET acceptor) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and that I232T polymorphism may exhibit an enhanced FRET efficiency. With de-quenching assay (<xref ref-type="bibr" rid="bib1">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Xu et al., 2008</xref>) on A20II1.6 B cells expressing similar level of either mTFP-232I or mTFP-232T (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>), we find that I232T polymorphic change indeed enhances the FRET efficiency about two folds, from ~20% in 232I to ~40% in 232T (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). This enhancement of FRET efficiency by I232T polymorphism indicates that 232T ectodomain prefers to a more recumbent orientation on the plasma membrane than 232I, consistent with above MDS observations.</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.46689.009</object-id><label>Figure 2.</label><caption><title>The 232T ectodomain prefers to a more recumbent orientation on the plasma membrane.</title><p>(<bold>A</bold>) Schematic of mTFP-R18 FRET experimental setup to measure the FRET signals between the ectodomain of 232I (green) or 232T (blue) (N-terminal of ectodomain fused with mTFP as FRET donor, cyan) and the plasma membrane (stained with R18 dye as FRET acceptor, red). (<bold>B</bold>) Comparison of mTFP fluorescence intensities of A20II1.6 B cell lines expressing either mTFP-232I (green) or mTFP-232T (blue) constructs by FACS analysis. (<bold>C</bold>) Representative images of de-quenching FRET assay. R18-labeled mTFP-232I or mTFP-232T cell images were acquired in both channels before or after R18 photo-bleaching (BP or AP). (<bold>D</bold>) FRET efficiency comparison of mTFP-232I (green circle) and mTFP-232T (blue square) cells (~20 cells, respectively) with a p-value indicated. Error bars represent SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig2-v2.tif"/></fig><p>Ectodomain orientation change of a receptor can significantly affect its in situ binding affinity with its ligands (<xref ref-type="bibr" rid="bib10">Huang et al., 2004</xref>). We therefore predicted that titling FcγRIIB ectodomain toward plasma membrane by I232T polymorphic change may attenuate its ligand binding affinity, especially the ligand association rate. To test this hypothesis, we applied well-established single-cell biomechanical apparatus with adhesion frequency assay (<xref ref-type="bibr" rid="bib2">Chesla et al., 1998</xref>; <xref ref-type="bibr" rid="bib11">Huang et al., 2010</xref>) to directly and quantitatively measure in situ two-dimensional (2D) binding kinetics of either 232I or 232T binding with its ligands (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The results show that the in situ 2D effective binding affinity of 232I with human IgG1 antibody (anti-MERS virus S protein, or anti-S) is about three times higher than that of 232T (<italic>A</italic><sub>c</sub><italic>K</italic><sub>a</sub> = 3.03 ± 0.15×10<sup>−7</sup> and 0.80 ± 0.04 × 10<sup>−7</sup> μm<sup>4</sup>, respectively), whereas that with human IgG4 is hardly measured as FcγRIIB and IgG4 binding is known to be extremely weak and beyond the detection limit (10<sup>−8</sup> μm<sup>4</sup>) of this assay (<xref ref-type="bibr" rid="bib11">Huang et al., 2010</xref>) (<xref ref-type="fig" rid="fig3">Figure 3B and F</xref>). Further analyses show that although the 2D off-rates of 232I and 232T from human IgG1 are similar (7.75 ± 1.42 and 7.62 ± 1.41 s<sup>−1</sup>, respectively) (<xref ref-type="fig" rid="fig3">Figure 3B and H</xref>), the 2D effective on-rate of 232T with IgG1 is three times slower than that of 232I (<xref ref-type="fig" rid="fig3">Figure 3B and G</xref>). These results are also confirmed by using another human IgG1 antibody (anti-HIV1 gp120 IgG1, or anti-gp120). Both 2D effective affinity and on-rate of 232I with anti-gp120 human IgG1 are three times higher than those of 232T (<italic>A</italic><sub>c</sub><italic>K</italic><sub>a</sub> = 7.74 ± 0.24×10<sup>−7</sup> and 2.43 ± 0.11 × 10<sup>−7</sup> μm<sup>4</sup>, respectively; <italic>A</italic><sub>c</sub><italic>k</italic><sub>on</sub>=5.95±0.19 and 2.16 ± 0.10 × 10<sup>−7</sup> μm<sup>4</sup> s<sup>−1</sup>, respectively), while the respective off-rates are similar (7.70 ± 0.83 and 8.90 ± 1.61 s<sup>−1</sup>, respectively) (<xref ref-type="fig" rid="fig3">Figure 3C and F–H</xref>). I232T polymorphic change also causes the reduction of 2D affinity and on-rate of FcγRIIB’s binding with other IgG subtypes (e.g. IgG2 and IgG3) (<xref ref-type="fig" rid="fig3">Figure 3D–H</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.46689.010</object-id><label>Figure 3.</label><caption><title>232T exhibits significantly reduced 2D IgG binding affinity and on-rate in comparison with 232I.</title><p>(<bold>A</bold>) Schematics of experimental setup for single-cell in situ 2D kinetic measurement. Two opposing micropipettes aspirated a human red blood cell coated with a monoclonal IgG (red) and an A20II1.6 B cell expressing either 232I or 232T (green) to operate contact-retraction cycles manipulation, respectively. (<bold>B–H</bold>) Plots of adhesion frequency <italic>P</italic><sub>a</sub> <italic>versus</italic> contact time <italic>t</italic><sub>c</sub> of FcγRIIB (either 232I or 232T) binding with human IgG1 antibody (anti-S, B, or anti-gp120, (<bold>C</bold>)/IgG2 (<bold>D</bold>)/IgG3 (<bold>E</bold>), corresponding in situ 2D effective binding affinity <italic>A</italic><sub>c</sub><italic>K</italic><sub>a</sub> (<bold>F</bold>), on-rate <italic>A</italic><sub>c</sub><italic>k</italic><sub>on</sub> (<bold>G</bold>) and off-rate <italic>k</italic><sub>off</sub> (<bold>H</bold>) are compared, respectively. <italic>m</italic><sub>FcγRIIB</sub> and <italic>m</italic><sub>IgG</sub> are surface molecular densities of respective proteins. Error bars represent SEM. ND, not detectable. <italic>NS</italic>, not significantly different.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46689.011</object-id><label>Figure 3—figure supplement 1.</label><caption><title>232T exhibits significantly reduced 2D affinity and on-rate of binding to IgG1 (anti-gp120) in comparison with 232I, although FcγRIIB (either 232I or 232T) A20II1.6 B cells are fixed by 4% paraformaldehyde (PFA) plus 4% sucrose.</title><p>(<bold>A</bold>) Adhesion curves of FcγRIIB (either 232I or 232T) and human IgG1 (anti-gp120) according to probabilistic kinetic model. (<bold>B–D</bold>) Comparisons of in situ 2D effective binding affinity (<italic>A</italic><sub>c</sub><italic>K</italic><sub>a</sub>) (<bold>B</bold>), on-rate (<italic>A</italic><sub>c</sub><italic>k</italic><sub>on</sub>) (<bold>C</bold>) and off-rate (<italic>k</italic><sub>off</sub>) (<bold>D</bold>) between 232I and 232T binding to IgG1 when cells are fixed. Error bars represent SEM. <italic>NS</italic>, not significantly different.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.46689.012</object-id><label>Figure 3—figure supplement 2.</label><caption><title>FcγRIIIA-158V shows a higher 2D affinity than FcγRIIIA-158F in binding with IgG1.</title><p>(<bold>A</bold>) Adhesion curves of FcγRIIIA (158F or 158V) and human IgG1 antibody (anti-S) according to probabilistic kinetic model. (<bold>B</bold>) From the adhesion curves, in situ 2D effective binding affinities (<italic>A</italic><sub>c</sub><italic>K</italic><sub>a</sub>) were calculated. Error bars represent SEM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-46689-fig3-figsupp2-v2.tif"/></fig></fig-group><p>Furthermore, we aimed to rule out other factors that may potentially reduce ligand binding affinity of 232T. First, we fixed either 232I or 232T expressing B cells to exclude the effect from the reduced lateral diffusion by I232T (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>). We find that fixing B cells expressing FcγRIIB by paraformaldehyde (PFA) does not alter the ligand binding defects for I232T polymorphic change (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), suggesting the reduction of lateral diffusion by I232T hardly contributes to the reduction of the ligand binding affinity and on-rate. Moreover, Zhu and colleagues have also extensively discussed and experimentally proved that the lateral diffusion has negligible impact on 2D affinity of receptor-ligand binding on live cells (<xref ref-type="bibr" rid="bib3">Chesla et al., 2000</xref>). To further exclude potential technical artifacts in in situ single-cell adhesion frequency assay, we confirm previously known binding-enhancing FcγRIIIA-F158V polymorphism by using the 2D binding assay in this report (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). All these data strongly support that I232T polymorphic change in the TM domain of FcγRIIB allosterically tilts FcγRIIB ectodomains toward the plasma membrane, rendering steric hindrance of its ligand binding domain. As a result, 232T exhibits significantly reduced 2D affinity and association on-rate to IgG antibodies. To be noted, it is possible that similar allosteric regulation may be applied to a broad range of transmembrane receptors, for example, potentially explaining how membrane anchor pattern of CD16a influences ligand recognition (<xref ref-type="bibr" rid="bib3">Chesla et al., 2000</xref>).</p><p>In summary, we confirm that homozygous FcγRIIB-I232T confers dramatically increased risk of developing more severe clinical manifestations in patients with SLE. The pathological relevant of I232T is caused by the inclination of the TM domain which leads to FcγRIIB ectodomain bending toward plasma membrane, significantly impairing FcγRIIB’s binding ability to IgG’s Fc portion through reducing in situ binding affinity and association rate. The hampered Fc recognition ability of FcγRIIB-I232T results in the deficiency on its inhibitory function and thus hyper-activated immune cells, potentially contributing to SLE.</p></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Cell line <break/>(<italic>Mus musculus</italic>)</td><td>A20II1.6 B cell</td><td>ATCC</td><td/><td>a gift from S.K. Pierce (National Institute of Allergy and Infectious Diseases, Bethesda, MD)</td></tr><tr><td>Cell line <break/>(<italic>Mus musculus</italic>)</td><td>232I A20II1.6 B cell line</td><td>(<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>)</td><td/><td/></tr><tr><td>Cell line <break/>(<italic>Mus musculus</italic>)</td><td>232T A20II1.6 B cell line</td><td>(<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>)</td><td/><td/></tr><tr><td>Cell line <break/>(<italic>Mus musculus</italic>)</td><td>mTFP-232I A20II1.6 B cell line</td><td>This paper</td><td/><td>Stable mTFP-232I expressing A20II1.6 B cell lines were acquired by lentivirus infection.</td></tr><tr><td>Cell line <break/>(<italic>Mus musculus</italic>)</td><td>mTFP-232T A20II1.6 B cell line</td><td>This paper</td><td/><td>Stable mTFP-232T expressing A20II1.6 B cell lines were acquired by lentivirus infection.</td></tr><tr><td>Antibody</td><td>Anti-gp120 IgG1, human monoclonal</td><td>a kind gift from Dr. Y. Shi, The Institute of Microbiology of the Chinese Academy of Sciences</td><td/><td>Dosage: 20 μg</td></tr><tr><td>Antibody</td><td>Anti-S IgG1, human monoclonal</td><td>a kind gift from Dr. L. Zhang and X. Wang, Tsinghua University</td><td/><td>Dosage: 20 μg</td></tr><tr><td>Antibody</td><td>IgG2, human monoclonal</td><td>a kind gift from Dr. H. Wang, Hisun, China</td><td>RANKL human IgG2 monoclonal antibody (HS629)</td><td>Dosage: 20 μg</td></tr><tr><td>Antibody</td><td>IgG3, human monoclonal</td><td>InvivoGen</td><td>Catalog#bgal-mab3; RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2810285">AB_2810285</ext-link></td><td>recombinant Anti-β-Gal-hIgG3 was produced in CHO cells; dosage: 20 μg</td></tr><tr><td>Antibody</td><td>IgG4, human monoclonal</td><td>a kind gift from Dr. Y. Shi, The Institute of Microbiology of the Chinese Academy of Sciences</td><td/><td>Dosage: 20 μg</td></tr><tr><td>Recombinant DNA reagent</td><td>PHAGE-mTFP-232I (plasmid)</td><td>This paper</td><td/><td>mTFP was fused to N-terminal of FcγRIIB-232I in a pHAGE backbone</td></tr><tr><td>Recombinant DNA reagent</td><td>PHAGE-mTFP-232T (plasmid)</td><td>This paper</td><td/><td>mTFP was fused to N-terminal of FcγRIIB-232T in a pHAGE backbone</td></tr><tr><td>Commercial assay or kit</td><td>TIANamp Blood DNA Midi Kit</td><td>TIANGEN Biotech, China</td><td>Catalog#DP332-01</td><td>TaqMan probe C: 5’-VIC-CGCTACAGCAGTCCCAGT-NFQ-3’, TaqMan Probe T: 5’-FAM-CGCTACAGCAATCCCAGT-NFQ-3’</td></tr><tr><td>Commercial assay or kit</td><td>TaqMan Genotyping Assays</td><td>Life Technology</td><td>Catalog#4351376</td><td/></tr><tr><td>Commercial assay or kit</td><td>ClonExpress MultiS One Step Cloning Kit</td><td>Vazyme, China</td><td>Catalog#C113</td><td/></tr><tr><td>Chemical compound, drug</td><td>Octadecyl rhodamine B (R18)</td><td>Invitrogen</td><td>Catalog#O246</td><td/></tr><tr><td>Chemical compound, drug</td><td>Biotin-PEG-SGA</td><td>JenKem Technology, China</td><td>Catalog#ZZ324P050</td><td/></tr><tr><td>Chemical compound, drug</td><td>Streptavidin</td><td>Sangon Biotech, China</td><td>Catalog#C600432</td><td/></tr><tr><td>Chemical compound, drug</td><td>EZ-Link Sulfo-NHS-LC-Biotin kits</td><td>Thermo Fisher Scientific</td><td>Catalog#21435</td><td/></tr><tr><td>Software, algorithm</td><td>VMD (Visual Molecular Dynamics)</td><td>University of Illinois at Urbana-Champaign</td><td>Visual Molecular Dynamics, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_001820">SCR_001820</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="http://www.ks.uiuc.edu/Research/vmd/">http://www.ks.uiuc.edu/Research/vmd/</ext-link></td></tr><tr><td>Software, algorithm</td><td>NAMD</td><td>University of Illinois at Urbana-Champaign</td><td>NAMD, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014894">SCR_014894</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="http://www.ks.uiuc.edu/Research/namd/">http://www.ks.uiuc.edu/Research/namd/</ext-link></td></tr><tr><td>Software, algorithm</td><td>CHARMM Force Field</td><td>Alex Mackerell lab at School of Pharmacy, University of Maryland</td><td/><td><ext-link ext-link-type="uri" xlink:href="http://mackerell.umaryland.edu/charmm_ff.shtml">http://mackerell.umaryland.edu/charmm_ff.shtml</ext-link></td></tr><tr><td>Software, algorithm</td><td>GraphPad Prism</td><td>GraphPad</td><td>GraphPad Prism, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td></tr></tbody></table></table-wrap><sec id="s3-1"><title>SNP rs1050501 genotyping and statistical analysis</title><p>The ethics committee of Peking University People's Hospital approved this study and informed consents were obtained from each patient and healthy volunteer. All the human-cell-associated experimental guidelines were approved by the Medical Ethics Committee of Peking University People’s Hospital (approval no. 2014PHB116-01) and by the Medical Ethics Committee of Tsinghua University (approval no. 20180029). There were 711 patients fulfilling the 1997 revised classification criteria of the American College of Rheumatology that enrolled in this study. Healthy volunteers were recruited as controls. 4–8 ml peripheral blood was acquired from SLE patients and healthy volunteers. Genomic DNA was extracted from peripheral blood samples using the TIANamp Blood DNA Midi Kit (Catalog#DP332-01, TIANGEN Biotech, China) following the manufacturer’s protocol. The TaqMan Genotyping Assays were applied for genotyping of SNP rs1050501 (TaqMan probe C: 5’-VIC-CGCTACAGCA GTCCCAGT-NFQ-3’, TaqMan Probe T: 5’-FAM- CGCTACAGCA ATCCCAGT-NFQ-3’) (Catalog#4351376, Life Technology). Amplification and genotyping analyses were performed using ABI 7300 Real-Time PCR system. Relative quantification of probes levels was calculated (7500 Sequence Detection System Software Version 1.4, ABI). Few samples were genotyped by using primers (forward: 5’-AAGGGGAGCC CTTCCCTCTGTT-3’, reverse: 5’-CATCACCCAC CATGTCTCAC-3’) binding to the flanking introns of exon five as reported (<xref ref-type="bibr" rid="bib9">Floto et al., 2005</xref>; <xref ref-type="bibr" rid="bib13">Kono et al., 2005</xref>). The DNA sequencing was done by BGI (Beijing). The Pearson chi-square tests were performed for the comparison of differences between cases and controls at genotype model (recessive model CC vs. TT+TC). The odds ratios (OR), 95% confidence intervals (CI) and <italic>p</italic> value for recessive model analysis were calculated using logistic regression, adjusting for age and sex. In statistical analyses, <italic>p</italic> value of less than 0.05 was considered statistically significant.</p></sec><sec id="s3-2"><title>Molecular dynamics simulations</title><p>Structure models of human FcγRIIB system (residues A46-I310) were built by fusing the crystal structure of the ectodomain (PDB code 2FCB, residues A46-Q215) to the transmembrane (TM) helix (residues M222-R248) model obtained in the previous study (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>). The stalk (residues A216-P221) and cytoplasmic regions (residues K249-I310) were randomly placed. Different initial models were built to minimize possible artifacts in structural modeling. An asymmetric lipid bilayer with the membrane lateral area of 100 × 100 Å<sup>2</sup> was generated with Membrane Builder in CHARMM-GUI (<xref ref-type="bibr" rid="bib25">Wu et al., 2014</xref>). The outer leaflet of lipid membrane contained PC, SM, and cholesterol with molar ratio 1:1:1, and the inner leaflet of lipid membrane contained PE, PC, PS, PIP2 and cholesterol with molar ratio 4:3:2:1:5. Different length of the lipid models were used, including the widely used PO series (16:0/18:1) which is the most common lipid within mammalian cell membranes, and other two lipid models with shorter (14:0/16:1) and longer (18:0/20:1) fatty acids. FcγRIIB models were inserted into the lipid membranes with its TM perpendicular to the bilayer surface and the ectodomain stands straight, as shown in <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</p><p>The 232I system was subsequently solvated in 100 × 100 × 203 Å<sup>3</sup> rectagular water boxes with TIP3P water model and was neutralized by 0.15 M NaCl. The 232T system was obtained from the same configuration using the Mutator plugin of VMD (<xref ref-type="bibr" rid="bib12">Humphrey et al., 1996</xref>). The final systems contained ~0.20 million atoms in total.</p><p>Both systems were first pre-equilibrated with the following three steps: (1) 5000 steps energy minimization with the heavy atoms of proteins and the head group of the lipids fixed, followed by two ns equilibration simulation under one fs timestep with these atoms constrained by five kcal/mol/Å<sup>2</sup> spring; (2) 5000 steps energy minimization with the heavy atoms of protein fixed, followed by 2 ns equilibration simulation under 1 fs timestep with these atoms constrained by 1 kcal/mol/Å<sup>2</sup> spring; (3) 4 ns equilibration simulation under 2 fs timestep with the heavy atoms of protein ecto- and TM domains constrained (i.e. the stalk and intracellular portion is free) by 0.2 kcal/mol/Å<sup>2</sup> spring.</p><p>The resulted systems were subjected to productive simulations for 200 ns with 2 fs timestep without any constrains, and the snapshots of the last 80 ns (sampled at 10 ps intervals) were used for detailed analyses including the probability distributions of hydrogen bonds, tilting angles of the TM helix, inclination angles of ectodomain, the distance between Ig-like C2-type one domain and lipid bilayer. The tilting angle of TM helix was defined as the angle between TM helix and membrane plane, similar as that used in previous study (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>). The inclination angle of ectodomain was defined as the angle between the membrane plane and the vector linking N-terminal of TM helix (M222-I224) and linker region of Ig-like C2-type 1 and 2 domain (S130-W132). The distance between Ig-like C2-type one domain and lipid bilayer was defined as the length between center of mass (COM) of this domain and the heavy atoms of phospholipid head in the normal direction of bilayer.</p><p>All simulations were performed with NAMD2 software (<xref ref-type="bibr" rid="bib19">Phillips et al., 2005</xref>) using CHARMM36m force field with the CMAP correction (<xref ref-type="bibr" rid="bib17">MacKerell et al., 1998</xref>). The simulations were performed in NPT ensemble (one atm, 310K) using a Langevin thermostat and Nosé-Hoover Langevin piston method (<xref ref-type="bibr" rid="bib8">Feller et al., 1995</xref>), respectively. 12 Å cutoff with 10 to 12 Å smooth switching was used for the calculation of the van der Waals interactions. The electrostatic interactions were computed using the particle mesh Eward method under periodic boundary conditions. The system preparations and illustrations were conducted using VMD.</p></sec><sec id="s3-3"><title>Plasmid construction and cell lines establishment</title><p>232I and 232T pHAGE plasmids were previously constructed (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>). mTFP was fused to N-terminal of either 232I or 232T in a pHAGE backbone by ClonExpress MultiS One Step Cloning Kit (Catalog#C113, Vazyme, China). Stable mTFP-232I/mTFP-232T expressing A20II1.6 B cell lines were acquired by lentivirus infection (three-vector system: mTFP-232I or mTFP-232I pHAGE, psPAX2, and pMD2.G). A20II1.6 B cell lines expressing similar level of either mTFP-232I or mTFP-232T were obtained by multiple rounds of cell sorting (Beckman moflo Astrios EQ). Either 232I or 232T expressing A20II1.6 B cell line was previously established (<xref ref-type="bibr" rid="bib29">Xu et al., 2016</xref>).</p></sec><sec id="s3-4"><title>FRET measurement</title><p>FRET measurements were performed as previously described (<xref ref-type="bibr" rid="bib1">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Xu et al., 2008</xref>). Briefly, all FRET measurements were carried out on Nikon TiE C2 confocal microscope with 100x oil lens, Argon 457 nm and HeNe 561 nm laser. 1 × 10<sup>6</sup> mTFP-232I or mTFP-232T expressing A20II1.6 B cells were stained with 300 nM octadecyl rhodamine B (R18) (Catalog#O246, Invitrogen) on ice for 3 min, excited by two lasers sequentially, and imaged before and after R18 photo-bleaching. mTFP intensity was processed through Image J. FRET efficiency was then calculated by (DQ−Q)/DQ, where DQ and Q are de-quenched and quenched mTFP intensity, respectively. FRET efficiencies of mTFP-232I and mTFP-232T cells (~20 cells, respectively) were calculated and plotted through Prism 7 (GraphPad). Error bars represent SEM.</p></sec><sec id="s3-5"><title>RBC preparation</title><p>Streptavidin (SA) coated red blood cells (SA-RBCs) preparation have been described previously (<xref ref-type="bibr" rid="bib11">Huang et al., 2010</xref>). Briefly, RBCs freshly collected from finger prick were biotinylated with biotin-PEG-SGA (Catalog#ZZ324P050, JenKem Technology, China) (<xref ref-type="bibr" rid="bib16">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Wu et al., 2019</xref>), followed by incubation with streptavidin (Catalog#C600432, Sangon Biotech, China) to make SA-RBCs. Human antibodies (anti-gp120 IgG1 and IgG4, a kind gift from Dr. Y. Shi, The Institute of Microbiology of the Chinese Academy of Sciences; anti-S IgG1, a kind gift from Dr. L. Zhang and X. Wang, Tsinghua University; IgG2, a kind gift from Dr. H. Wang, Hisun, China; IgG3, Catalog#bgal-mab3, InvivoGen) were biotinylated by EZ-Link Sulfo-NHS-LC-Biotin kits (Catalog# 21435, Thermo Fisher Scientific). Different amount of biotinylated IgG was linked into SA-RBCs through SA-biotin interaction at RT for 30 min, respectively to produce IgG-coated RBCs. These IgG-coated RBCs were then used to measure 2D binding kinetics of FcγRIIB/IgG with adhesion frequency assay. All above experimental processes were approved by the institutional ethical review board of Zhejiang University (approval no. 2015–006).</p></sec><sec id="s3-6"><title>Adhesion frequency assay</title><p>The adhesion frequency assay was applied to measure FcγRIIB/IgG in situ 2D binding kinetics. The detail experimental setup and procedure were previously described (<xref ref-type="bibr" rid="bib11">Huang et al., 2010</xref>). In brief, two opposing micropipettes aspirating the RBC and FcγRIIB-expressing A20II1.6 B cell (either 232I or 232T) respectively were controlled by a customized computer program to operate contact-retraction cycles. Through 50 contact-retraction cycles, the binding frequency <italic>P</italic><sub>a</sub> was acquired with definite contact area <italic>A</italic><sub>c</sub> and a series of preset contact time <italic>t</italic><sub>c</sub> (0.1, 0.2, 0.5, 1, 2 s or longer). 3 ~ 4 cell pairs were tested for each contact time. And these data were then non-linearly fitted to obtain effective 2D binding affinity <italic>A</italic><sub>c</sub><italic>K</italic><sub>a</sub> and off-rate <italic>k</italic><sub>off</sub> by probabilistic kinetic model (<xref ref-type="bibr" rid="bib2">Chesla et al., 1998</xref>):<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula>where <italic>m</italic><sub>r</sub> and <italic>m</italic><sub>l</sub> are receptor and ligand densities on cells, respectively. Effective 2D on-rate <italic>A</italic><sub>c</sub><italic>k</italic><sub>on</sub> was then calculated as following:<disp-formula id="equ2"><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>In order to accurately calculate 2D binding affinity and on-rate, these two molecular densities (<italic>m</italic><sub>FcγRIIB</sub> and <italic>m</italic><sub>IgG</sub>) were determined by standard calibration beads (Quantum Alexa Fluor647 MESF kit, Catalog#647, Bangs Laboratories) on flow cytometry (Beckman CytoFLEX S), respectively. Binding kinetics were calculated and plotted through Prism 7 (GraphPad). Error bars represent SEM.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Y Shi from The Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) for kindly providing us HIV1 gp120 human IgG1 and PD1 human IgG4 antibody, Dr. L Zhang and X Wang from Tsinghua University for kindly providing us MERS virus S protein human IgG1 antibody, Zhejiang Hisun Pharmaceutical Co., LTD and Dr. H Wang for kindly providing us RANKL human IgG2 monoclonal antibody (HS629), core facilities in Zhejiang University School of Medicine for technical supports, especially X Song for FACS supports. This work was supported by grants from the National Basic Research Program of China (2015CB910800 to WChen), the National Science Foundation of China (31470900 and 31522021 to W Chen; 11672317 to J Lou; 11772348 to Y Zhang), the Fundamental Research Funds for the Central Universities (2015XZZX004-32 to W Chen). The computational resources were provided by the National Supercomputing Center Tianjin Center and HPC-Service Station at the Center for Biological Imaging of the Institute of Biophysics.</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Methodology, Writing—original draft, Writing—review and editing, Designed the project, Performed FRET and adhesion frequency assay</p></fn><fn fn-type="con" id="con2"><p>Software, Funding acquisition, Investigation, Methodology, Writing—original draft, Writing—review and editing, Designed the project, Performed MD simulations</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Writing—review and editing, Designed the project, Performed SNP rs1050501 genotyping and statistical analysis</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Performed FRET and adhesion frequency assay</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Prepared reagents, Performed antibody biotinylation</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Prepared reagents, Performed antibody biotinylation</p></fn><fn fn-type="con" id="con7"><p>Supervision, Methodology, Performed SNP rs1050501 genotyping and statistical analysis</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Writing—original draft, Project administration, Writing—review and editing, Conceived the project, Designed the project</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing—review and editing, Conceived the project, Designed the project, Performed MD simulations</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing—review and editing, Conceived the project, Designed the project</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The ethics committee of Peking University People's Hospital approved this study and informed consents were obtained from each patient and healthy volunteer. All the human cell associated experimental guidelines were approved by the Medical Ethics Committee of Peking University People's Hospital (approval no. 2014PHB116-01) and by the Medical Ethics Committee of Tsinghua University (approval no. 20180029).</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.46689.013</object-id><label>Supplementary file 1.</label><caption><title>Association analysis of rs1050501 with SLE (adjusted for sex and age).</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-46689-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.46689.014</object-id><label>Supplementary file 2.</label><caption><title>Demographic characteristic of SLE cohort.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-46689-supp2-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.46689.015</object-id><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-46689-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s6" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Pan</surname> <given-names>W</given-names></name><name><surname>Sui</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Qi</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Acidic phospholipids govern the enhanced activation of IgG-B cell receptor</article-title><source>Nature Communications</source><volume>6</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/ncomms9552</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesla</surname> <given-names>SE</given-names></name><name><surname>Selvaraj</surname> <given-names>P</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Measuring two-dimensional receptor-ligand binding kinetics by micropipette</article-title><source>Biophysical Journal</source><volume>75</volume><fpage>1553</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(98)74074-3</pub-id><pub-id pub-id-type="pmid">9726957</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesla</surname> <given-names>SE</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Nagarajan</surname> <given-names>S</given-names></name><name><surname>Selvaraj</surname> <given-names>P</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The membrane anchor influences ligand binding two-dimensional kinetic rates and three-dimensional affinity of FcgammaRIII (CD16)</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><fpage>10235</fpage><lpage>10246</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.14.10235</pub-id><pub-id pub-id-type="pmid">10744709</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname> <given-names>ZT</given-names></name><name><surname>Tsuchiya</surname> <given-names>N</given-names></name><name><surname>Kyogoku</surname> <given-names>C</given-names></name><name><surname>Ohashi</surname> <given-names>J</given-names></name><name><surname>Qian</surname> <given-names>YP</given-names></name><name><surname>Xu</surname> <given-names>SB</given-names></name><name><surname>Mao</surname> <given-names>CZ</given-names></name><name><surname>Chu</surname> <given-names>JY</given-names></name><name><surname>Tokunaga</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Association of fcgamma receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in chinese: a common susceptibility gene in the asian populations</article-title><source>Tissue Antigens</source><volume>63</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0039.2004.00142.x</pub-id><pub-id pub-id-type="pmid">14651519</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clatworthy</surname> <given-names>MR</given-names></name><name><surname>Willcocks</surname> <given-names>L</given-names></name><name><surname>Urban</surname> <given-names>B</given-names></name><name><surname>Langhorne</surname> <given-names>J</given-names></name><name><surname>Williams</surname> <given-names>TN</given-names></name><name><surname>Peshu</surname> <given-names>N</given-names></name><name><surname>Watkins</surname> <given-names>NA</given-names></name><name><surname>Floto</surname> <given-names>RA</given-names></name><name><surname>Smith</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria</article-title><source>PNAS</source><volume>104</volume><fpage>7169</fpage><lpage>7174</lpage><pub-id pub-id-type="doi">10.1073/pnas.0608889104</pub-id><pub-id pub-id-type="pmid">17435165</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Ambrosio</surname> <given-names>D</given-names></name><name><surname>Fong</surname> <given-names>DC</given-names></name><name><surname>Cambier</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The SHIP phosphatase becomes associated with fc gammaRIIB1 and is tyrosine phosphorylated during 'negative' signaling</article-title><source>Immunology Letters</source><volume>54</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/S0165-2478(96)02653-3</pub-id><pub-id pub-id-type="pmid">9052858</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal Porto</surname> <given-names>JM</given-names></name><name><surname>Gauld</surname> <given-names>SB</given-names></name><name><surname>Merrell</surname> <given-names>KT</given-names></name><name><surname>Mills</surname> <given-names>D</given-names></name><name><surname>Pugh-Bernard</surname> <given-names>AE</given-names></name><name><surname>Cambier</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>B cell antigen receptor signaling 101</article-title><source>Molecular Immunology</source><volume>41</volume><fpage>599</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2004.04.008</pub-id><pub-id pub-id-type="pmid">15219998</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feller</surname> <given-names>SE</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Pastor</surname> <given-names>RW</given-names></name><name><surname>Brooks</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Constant pressure molecular dynamics simulation: the langevin piston method</article-title><source>The Journal of Chemical Physics</source><volume>103</volume><fpage>4613</fpage><lpage>4621</lpage><pub-id pub-id-type="doi">10.1063/1.470648</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floto</surname> <given-names>RA</given-names></name><name><surname>Clatworthy</surname> <given-names>MR</given-names></name><name><surname>Heilbronn</surname> <given-names>KR</given-names></name><name><surname>Rosner</surname> <given-names>DR</given-names></name><name><surname>MacAry</surname> <given-names>PA</given-names></name><name><surname>Rankin</surname> <given-names>A</given-names></name><name><surname>Lehner</surname> <given-names>PJ</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name><name><surname>Allen</surname> <given-names>JM</given-names></name><name><surname>Watkins</surname> <given-names>NA</given-names></name><name><surname>Smith</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts</article-title><source>Nature Medicine</source><volume>11</volume><fpage>1056</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1038/nm1288</pub-id><pub-id pub-id-type="pmid">16170323</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Chesla</surname> <given-names>SE</given-names></name><name><surname>Yago</surname> <given-names>T</given-names></name><name><surname>Mehta</surname> <given-names>P</given-names></name><name><surname>McEver</surname> <given-names>RP</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name><name><surname>Long</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Quantifying the effects of molecular orientation and length on two-dimensional receptor-ligand binding kinetics</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>44915</fpage><lpage>44923</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407039200</pub-id><pub-id pub-id-type="pmid">15299021</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Zarnitsyna</surname> <given-names>VI</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Edwards</surname> <given-names>LJ</given-names></name><name><surname>Jiang</surname> <given-names>N</given-names></name><name><surname>Evavold</surname> <given-names>BD</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness</article-title><source>Nature</source><volume>464</volume><fpage>932</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1038/nature08944</pub-id><pub-id pub-id-type="pmid">20357766</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname> <given-names>W</given-names></name><name><surname>Dalke</surname> <given-names>A</given-names></name><name><surname>Schulten</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>VMD: visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname> <given-names>H</given-names></name><name><surname>Kyogoku</surname> <given-names>C</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name><name><surname>Tsuchiya</surname> <given-names>N</given-names></name><name><surname>Honda</surname> <given-names>H</given-names></name><name><surname>Yamamoto</surname> <given-names>K</given-names></name><name><surname>Tokunaga</surname> <given-names>K</given-names></name><name><surname>Honda</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling</article-title><source>Human Molecular Genetics</source><volume>14</volume><fpage>2881</fpage><lpage>2892</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi320</pub-id><pub-id pub-id-type="pmid">16115811</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyogoku</surname> <given-names>C</given-names></name><name><surname>Dijstelbloem</surname> <given-names>HM</given-names></name><name><surname>Tsuchiya</surname> <given-names>N</given-names></name><name><surname>Hatta</surname> <given-names>Y</given-names></name><name><surname>Kato</surname> <given-names>H</given-names></name><name><surname>Yamaguchi</surname> <given-names>A</given-names></name><name><surname>Fukazawa</surname> <given-names>T</given-names></name><name><surname>Jansen</surname> <given-names>MD</given-names></name><name><surname>Hashimoto</surname> <given-names>H</given-names></name><name><surname>van de Winkel</surname> <given-names>JG</given-names></name><name><surname>Kallenberg</surname> <given-names>CG</given-names></name><name><surname>Tokunaga</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Fcgamma receptor gene polymorphisms in japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility</article-title><source>Arthritis &amp; Rheumatism</source><volume>46</volume><fpage>1242</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1002/art.10257</pub-id><pub-id pub-id-type="pmid">12115230</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Won Sohn</surname> <given-names>H</given-names></name><name><surname>Tolar</surname> <given-names>P</given-names></name><name><surname>Meckel</surname> <given-names>T</given-names></name><name><surname>Pierce</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Antigen-induced oligomerization of the B cell receptor is an early target of fc gamma RIIB inhibition</article-title><source>The Journal of Immunology</source><volume>184</volume><fpage>1977</fpage><lpage>1989</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902334</pub-id><pub-id pub-id-type="pmid">20083655</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Evavold</surname> <given-names>BD</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling</article-title><source>Cell</source><volume>157</volume><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.02.053</pub-id><pub-id pub-id-type="pmid">24725404</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKerell</surname> <given-names>AD</given-names></name><name><surname>Bashford</surname> <given-names>D</given-names></name><name><surname>Bellott</surname> <given-names>M</given-names></name><name><surname>Dunbrack</surname> <given-names>RL</given-names></name><name><surname>Evanseck</surname> <given-names>JD</given-names></name><name><surname>Field</surname> <given-names>MJ</given-names></name><name><surname>Fischer</surname> <given-names>S</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Ha</surname> <given-names>S</given-names></name><name><surname>Joseph-McCarthy</surname> <given-names>D</given-names></name><name><surname>Kuchnir</surname> <given-names>L</given-names></name><name><surname>Kuczera</surname> <given-names>K</given-names></name><name><surname>Lau</surname> <given-names>FT</given-names></name><name><surname>Mattos</surname> <given-names>C</given-names></name><name><surname>Michnick</surname> <given-names>S</given-names></name><name><surname>Ngo</surname> <given-names>T</given-names></name><name><surname>Nguyen</surname> <given-names>DT</given-names></name><name><surname>Prodhom</surname> <given-names>B</given-names></name><name><surname>Reiher</surname> <given-names>WE</given-names></name><name><surname>Roux</surname> <given-names>B</given-names></name><name><surname>Schlenkrich</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>JC</given-names></name><name><surname>Stote</surname> <given-names>R</given-names></name><name><surname>Straub</surname> <given-names>J</given-names></name><name><surname>Watanabe</surname> <given-names>M</given-names></name><name><surname>Wiórkiewicz-Kuczera</surname> <given-names>J</given-names></name><name><surname>Yin</surname> <given-names>D</given-names></name><name><surname>Karplus</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>All-atom empirical potential for molecular modeling and dynamics studies of proteins</article-title><source>The Journal of Physical Chemistry B</source><volume>102</volume><fpage>3586</fpage><lpage>3616</lpage><pub-id pub-id-type="doi">10.1021/jp973084f</pub-id><pub-id pub-id-type="pmid">24889800</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niederer</surname> <given-names>HA</given-names></name><name><surname>Clatworthy</surname> <given-names>MR</given-names></name><name><surname>Willcocks</surname> <given-names>LC</given-names></name><name><surname>Smith</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus</article-title><source>Annals of the New York Academy of Sciences</source><volume>1183</volume><fpage>69</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.05132.x</pub-id><pub-id pub-id-type="pmid">20146709</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname> <given-names>JC</given-names></name><name><surname>Braun</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Gumbart</surname> <given-names>J</given-names></name><name><surname>Tajkhorshid</surname> <given-names>E</given-names></name><name><surname>Villa</surname> <given-names>E</given-names></name><name><surname>Chipot</surname> <given-names>C</given-names></name><name><surname>Skeel</surname> <given-names>RD</given-names></name><name><surname>Kalé</surname> <given-names>L</given-names></name><name><surname>Schulten</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Scalable molecular dynamics with NAMD</article-title><source>Journal of Computational Chemistry</source><volume>26</volume><fpage>1781</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1002/jcc.20289</pub-id><pub-id pub-id-type="pmid">16222654</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pincetic</surname> <given-names>A</given-names></name><name><surname>Bournazos</surname> <given-names>S</given-names></name><name><surname>DiLillo</surname> <given-names>DJ</given-names></name><name><surname>Maamary</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>TT</given-names></name><name><surname>Dahan</surname> <given-names>R</given-names></name><name><surname>Fiebiger</surname> <given-names>BM</given-names></name><name><surname>Ravetch</surname> <given-names>JV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Type I and type II fc receptors regulate innate and adaptive immunity</article-title><source>Nature Immunology</source><volume>15</volume><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/ni.2939</pub-id><pub-id pub-id-type="pmid">25045879</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siriboonrit</surname> <given-names>U</given-names></name><name><surname>Tsuchiya</surname> <given-names>N</given-names></name><name><surname>Sirikong</surname> <given-names>M</given-names></name><name><surname>Kyogoku</surname> <given-names>C</given-names></name><name><surname>Bejrachandra</surname> <given-names>S</given-names></name><name><surname>Suthipinittharm</surname> <given-names>P</given-names></name><name><surname>Luangtrakool</surname> <given-names>K</given-names></name><name><surname>Srinak</surname> <given-names>D</given-names></name><name><surname>Thongpradit</surname> <given-names>R</given-names></name><name><surname>Fujiwara</surname> <given-names>K</given-names></name><name><surname>Chandanayingyong</surname> <given-names>D</given-names></name><name><surname>Tokunaga</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Association of fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais</article-title><source>Tissue Antigens</source><volume>61</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1034/j.1399-0039.2003.00047.x</pub-id><pub-id pub-id-type="pmid">12753656</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>KG</given-names></name><name><surname>Clatworthy</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications</article-title><source>Nature Reviews Immunology</source><volume>10</volume><fpage>328</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nri2762</pub-id><pub-id pub-id-type="pmid">20414206</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starbeck-Miller</surname> <given-names>GR</given-names></name><name><surname>Badovinac</surname> <given-names>VP</given-names></name><name><surname>Barber</surname> <given-names>DL</given-names></name><name><surname>Harty</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cutting edge: expression of fcγriib tempers memory CD8 T cell function in vivo</article-title><source>The Journal of Immunology</source><volume>192</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302232</pub-id><pub-id pub-id-type="pmid">24285839</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willcocks</surname> <given-names>LC</given-names></name><name><surname>Carr</surname> <given-names>EJ</given-names></name><name><surname>Niederer</surname> <given-names>HA</given-names></name><name><surname>Rayner</surname> <given-names>TF</given-names></name><name><surname>Williams</surname> <given-names>TN</given-names></name><name><surname>Yang</surname> <given-names>W</given-names></name><name><surname>Scott</surname> <given-names>JA</given-names></name><name><surname>Urban</surname> <given-names>BC</given-names></name><name><surname>Peshu</surname> <given-names>N</given-names></name><name><surname>Vyse</surname> <given-names>TJ</given-names></name><name><surname>Lau</surname> <given-names>YL</given-names></name><name><surname>Lyons</surname> <given-names>PA</given-names></name><name><surname>Smith</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus</article-title><source>PNAS</source><volume>107</volume><fpage>7881</fpage><lpage>7885</lpage><pub-id pub-id-type="doi">10.1073/pnas.0915133107</pub-id><pub-id pub-id-type="pmid">20385827</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>EL</given-names></name><name><surname>Cheng</surname> <given-names>X</given-names></name><name><surname>Jo</surname> <given-names>S</given-names></name><name><surname>Rui</surname> <given-names>H</given-names></name><name><surname>Song</surname> <given-names>KC</given-names></name><name><surname>Dávila-Contreras</surname> <given-names>EM</given-names></name><name><surname>Qi</surname> <given-names>Y</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Monje-Galvan</surname> <given-names>V</given-names></name><name><surname>Venable</surname> <given-names>RM</given-names></name><name><surname>Klauda</surname> <given-names>JB</given-names></name><name><surname>Im</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CHARMM-GUI membrane builder toward realistic biological membrane simulations</article-title><source>Journal of Computational Chemistry</source><volume>35</volume><fpage>1997</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1002/jcc.23702</pub-id><pub-id pub-id-type="pmid">25130509</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Fei</surname> <given-names>P</given-names></name><name><surname>Cui</surname> <given-names>L</given-names></name><name><surname>Qin</surname> <given-names>R</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Yao</surname> <given-names>D</given-names></name><name><surname>Martinez</surname> <given-names>RJ</given-names></name><name><surname>Hu</surname> <given-names>W</given-names></name><name><surname>An</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Fan</surname> <given-names>J</given-names></name><name><surname>Yin</surname> <given-names>W</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Zeng</surname> <given-names>X</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Evavold</surname> <given-names>BD</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Lou</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechano-regulation of Peptide-MHC class I conformations determines TCR antigen recognition</article-title><source>Molecular Cell</source><volume>73</volume><fpage>1015</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.12.018</pub-id><pub-id pub-id-type="pmid">30711376</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Gagnon</surname> <given-names>E</given-names></name><name><surname>Call</surname> <given-names>ME</given-names></name><name><surname>Schnell</surname> <given-names>JR</given-names></name><name><surname>Schwieters</surname> <given-names>CD</given-names></name><name><surname>Carman</surname> <given-names>CV</given-names></name><name><surname>Chou</surname> <given-names>JJ</given-names></name><name><surname>Wucherpfennig</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif</article-title><source>Cell</source><volume>135</volume><fpage>702</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.09.044</pub-id><pub-id pub-id-type="pmid">19013279</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Wan</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Shaheen</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Yue</surname> <given-names>C</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Brzostowski</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>YH</given-names></name><name><surname>Zheng</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Through an ITIM-independent mechanism the fcγriib blocks B cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19</article-title><source>The Journal of Immunology</source><volume>192</volume><fpage>5179</fpage><lpage>5191</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400101</pub-id><pub-id pub-id-type="pmid">24790152</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Xia</surname> <given-names>M</given-names></name><name><surname>Guo</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Yi</surname> <given-names>J</given-names></name><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>Xie</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Shen</surname> <given-names>Z</given-names></name><name><surname>Xue</surname> <given-names>B</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Meckel</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>YH</given-names></name><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Gong</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Impairment on the lateral mobility induced by structural changes underlies the functional deficiency of the lupus-associated polymorphism FcγRIIB-T232</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>2707</fpage><lpage>2727</lpage><pub-id pub-id-type="doi">10.1084/jem.20160528</pub-id><pub-id pub-id-type="pmid">27799621</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.46689.017</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing Editor</role><aff><institution>Osaka University</institution><country>Japan</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Takai</surname><given-names>Toshiyuki</given-names> </name><role>Reviewer</role></contrib><contrib contrib-type="reviewer"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewer</role><aff><institution>University of Oxford</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Dear Dr Chen,</p><p>Thank you for submitting your article &quot;FcγRIIB I232T polymorphic change allosterically suppresses ligand binding&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by Tadatsugu Taniguchi as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Toshiyuki Takai (Reviewer #1); Michael L Dustin (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The short report adds to data supporting a connection of I232T polymorphism in FcγRIIB to lupus. The paper then investigates the mechanism by bringing in a new idea from MD simulations that the molecules lies down on the surface and becomes less likely to bind ligand coming from another surface. The authors validate that the N-terminus of the FcR with the I232T is closer to the membrane using a good FRET method, and then use the adhesion frequency assay to determine that the 2D on-rate for initial bond formation is reduced 3-fold with no change in off-rate. This fits very well with the model and may explain other instances where changing the membrane anchor altered 2D kinetic rates.</p><p>There are a few issues to clarify.</p><p>1) The clinical data is quite different than the biophysical data that follows. It is implied that it adds to prior studies by showing a difference between heterozygous and homozygous for I232T for risk of lupus. Can the authors confirm that this is new finding in relation to the numerous prior studies cited?</p><p>2) The modelling of the distortion of the transmembrane-ectodomain interface (Figure 1) is based on a protein section (A216-P221) that is poorly defined structurally. How dependent are the effects on the composition/width of the model membrane? Is this representative of immune cell plasma membranes?</p><p>3) Does FcγRIIB-232T affect binding to all IgG subclasses (also IgG2 and IgG3)? One might expect this to be the case if affinity was altered based on differential rigidity/binding site occlusion. If this data is available or could be made available, it would add weight to the findings.</p><p>4) The authors might want to cite Xu et al. (2008) if they agree it was first to use this effective FRET pair.</p><p>5) That authors might want to cite Chesla et al. (2000) to indicate that others have found difficult to explain results after changing membrane anchor and perhaps this phenomenon might be invested in these situations.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.46689.018</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>[…]</p><p>There are a few issues to clarify.</p><p>1) The clinical data is quite different than the biophysical data that follows. It is implied that it adds to prior studies by showing a difference between heterozygous and homozygous for I232T for risk of lupus. Can the authors confirm that this is new finding in relation to the numerous prior studies cited?</p></disp-quote><p>Thank the reviewers for this comment. <italic>FCGR2B</italic> rs1050501 (c.695T &gt; C) codes an amino acid substitution, Ile232Thr (I232T) on chromosome 1q23.3 (161644048). There are a lot of published epidemiological papers, however those studies just showed that the homozygous genotype for I232T significantly increased the risk of SLE under recessive association model in world-wide populations (Chu et al., 2004; Floto et al., 2005; Kono et al., 2005; Kyogoku et al., 2002; Niederer et al., 2010; Siriboonrit et al., 2003; Willcocks et al., 2010). Although a statistical linkage of the homozygous FcγRIIB-I232T polymorphism with SLE is established, comprehensive assessments investigations towards the correlation of FcγRIIB-I232T regarding to the age of syndrome onset, progress, and clinical manifestation of SLE are still lacking.</p><p>In this study, we evaluate the susceptibility of <italic>FCGR2B</italic> rs1050501 to SLE in an enlarged Chinese SLE patient cohort with complete clinical documents. Therefore, for the first time, we establish a significant association of the homozygous FcγRIIB-I232T polymorphism with more severe SLE clinical manifestations in this report. In detail, we provide new information to show that SLE patients carrying homozygous FcγRIIB-I232T present significant elevation in the amounts of anti-dsDNA antibodies (<italic>p</italic>=0.004), anti-nuclear antibodies (<italic>p</italic>=0.021) and total Immunoglobulin (Ig) (<italic>p</italic>=0.032) in comparison to patients carrying heterozygous FcγRIIB-I232T polymorphism or FcγRIIB-WT (Table 1 in the revised manuscript). Moreover, homozygous FcγRIIB-I232T polymorphism is also significantly associated with the higher SLE disease activity index (SLEDAI) score (<italic>p</italic>=0.014 for SLEDAI≥12 vs. <italic>p</italic>=0.861 for SLEDAI&lt;12) as well as more severe clinical manifestations including arthritis (<italic>p</italic>=0.008), anemia (<italic>p</italic>=0.006), leukopenia (<italic>p</italic>=0.005), complement decrease (<italic>p</italic>=0.006), hematuria (<italic>p</italic>=0.004) and leucocyturia (<italic>p</italic>=0.010) (Table 1 in the revised manuscript). A suggestive association is also observed between homozygous FcγRIIB-I232T polymorphism and serositis (<italic>p</italic>=0.063) (Table 1 in the revised manuscript). These clinical association analyses demonstrate that SLE patients homozygous for FcγRIIB-I232T polymorphism are prone to develop more severe clinical manifestations than the patients carrying heterozygous FcγRIIB-I232T polymorphism or FcγRIIB-WT, reinforcing the importance to study the pathogenic mechanism of FcγRIIB-I232T polymorphism since this SNP occurs at a notable frequency in up to 40% (heterozygous polymorphism) humans.</p><p>Beyond all these clinical data, in-depth mechanistic investigations towards the inter-linkage of FcγRIIB-I232T regarding to the age of syndrome onset, progress, and clinical manifestation of SLE are still lacking. In the second part of this manuscript, the biophysical study provides a novel mechanism for the pathological relevance of I232T by showing that ectodomain harboring I232T polymorphism bends towards the membrane such that the Fc binding ability is significantly reduced. The hampered Fc recognition ability of FcγRIIB-I232T results in deficiency on its inhibitory function and thus, hyper-activated immune cells, potentially contributing to SLE.</p><disp-quote content-type="editor-comment"><p>2) The modelling of the distortion of the transmembrane-ectodomain interface (Figure 1) is based on a protein section (A216-P221) that is poorly defined structurally. How dependent are the effects on the composition/width of the model membrane? Is this representative of immune cell plasma membranes?</p></disp-quote><p>We fully agree with the reviewer on this point. We did use a structural model for the ectodomain-transmembrane interface, transmembrane and intracellular region of the FcγRIIB in our molecular dynamics simulations (MDS), as a solved structure of the full-length FcγRIIB or this portion alone is not available. To minimize any possible artifact from the modeled structure, we have carried out simulations starting from different initial models, and all these simulations converge into the same results, suggesting the validity and consistency of our simulations. Moreover, in our study, the simulations mainly function to provide testable hypotheses for further validations by all the following biochemical and biophysical experiments. Our main conclusions are drawn corroboratively by both simulations and experimental results.</p><p>The reviewer is quite right that the orientation of a transmembrane helix should depend on the composition of the lipid membrane. In our study, the membrane was built as an asymmetric lipid bilayer, with lipid composition mimicking a real plasma membrane of mammalian cells (Marique and Hildebrand, 1973; Pratt et al., 1978; Vanblitterswijk et al., 1982). The head group and the length of fatty acid tails are two key factors for a lipid molecule. In mammalian cells, the lipid head groups in outer leaflet includes mainly PC (phosphocholine) and SM (sphingomyelin), PE (phosphoethanolamine), and other types with minor percentages; the lipid head groups in the inner leaflet commonly includes PE, PC, PS (phosphoserine) and PI (phosphatidylinositol), while some cell membranes also include SM and other rare types of lipid head groups (Ingolfsson et al., 2014; Marrink et al., 2019).</p><p>The length of the fatty acid tails vary from 12 to 26 carbons in plasma membrane, with the 16 and 18 carbons tails most abundant (Pratt et al., 1978; Quehenberger et al., 2010; Vanblitterswijk et al., 1982). Cholesterol is also a major component in mammalian cells, and its molar ratio varies in different cell types. Its ratio to phospholipids ranges from 30% to 50 (Marique and Hildebrand, 1973; Pratt et al., 1978; Vanblitterswijk et al., 1982).</p><p>The lipid composition we used in our simulations is POPC/PSM/CHOL (1:1:1) for the outer leaflet and POPE/POPC/POPS/POPIP2/CHOL (4:3:2:1:5) for the inner leaflet, which is very close to previous known composition of the cell membrane of mammalian leukocytes (Andoh et al., 2013; Monneron and Dalayer, 1978; Pratt et al., 1978; Vanblitterswijk et al., 1982). The molar ratio of cholesterols is ~33% of total lipids, that is, ~50% for the cholesterol and phospholipids. Thus, our lipid model almost mimics the lipid composition of immune cell plasma membrane. Moreover, in the previous study, using a lipid bilayer model with PC lipids only, which differs significantly with the actual lipid composition in immune cell plasma membrane, the inclination of FcγRIIB-232T (232T) was also observed (Xu et al., 2016). Together with our current study, it can be suggested that our observation of 232T’s TM domain inclination is not affected by the head groups of lipids.</p><p>In our original manuscript, we only used 16:18 lipids for fatty acid chain length, which is widely accepted by most MD simulations involving a lipid bilayer. Nevertheless, it is possible that different lengths of the fatty acid chain may result in different thickness of the lipid membrane, which may affect the inclination of the TM domain as pointed out by the reviewer. To address the potential pitfalls, in this revised manuscript, we performed additional simulations with new lipid models with shorter (14:0/16:1) and longer (18:0/20:1) fatty acids respectively (Figure 1—figure supplement 4A, we would like to emphasize here that lipids with long fatty acids tail are very rare in cell membrane as shown in Vanblitterswijk et al., 1982). With these new lipid models, we carried out ~200 ns simulations using the same strategy as that in our initial study for both FcγRIIB-232I (232I) and 232T. The results demonstrate that the thickness of the lipid bilayer is indeed affected by the length of the fatty acid chain (Figure 1—figure supplement 4A), ~3.04 nm for 14:0/16:1 lipids, shorter than the ~3.54 nm for 16:0/18:1 lipids. For 18:0/20:1 lipids, the membrane thickness is further increased to ~4.19 nm (Figure 1—figure supplement 4A). As a result, the shorter lipid tail (14:0/16:1) promotes the most pronounced TM helix tilting (Figure 1—figure supplement 4B), and S218-P221 prolongation (Figure 1—figure supplement 4C). Interestingly, these phenomena can also be observed readily for a bilayer model with longer fatty acid chain (Figure 1—figure supplement 4B,C). These results confirm the validity of original finding.</p><disp-quote content-type="editor-comment"><p>3) Does FcγRIIB-232T affect binding to all IgG subclasses (also IgG2 and IgG3)? One might expect this to be the case if affinity was altered based on differential rigidity/binding site occlusion. If this data is available or could be made available, it would add weight to the findings.</p></disp-quote><p>To further determine whether FcγRIIB-I232T affects its binding to all IgG subclasses (also IgG2 and IgG3), we performed additional single-cell micropipette experiments to measure 2D affinities of 232I or 232T binding with human IgG2 or IgG3 monoclonal antibody respectively (Figure 3).</p><p>Our data indeed show that the in situ 2D effective binding affinity of 232I with human IgG2 monoclonal antibody (IgG2) is also about three times higher than that of 232T binding (<italic>A</italic><sub>c</sub><italic>K<sub>a</sub></italic>=6.82 ± 0.58×10<sup>-8</sup> and 2.26 ± 0.15×10<sup>-8</sup>μm<sup>4</sup>, respectively) (Figure 3F). Moreover, off-rates of 232I and 232T binding with IgG2 are very similar (5.56 ± 1.25 and 5.70 ± 1.24 s<sup>-1</sup>, respectively) (Figure 3H), while the 2D effective on-rate of 232T binding with IgG2 is three times slower than that of 232I (Figure 3G). So, it has similar reduction in both 2D affinity and on-rate by I232T polymorphic change.</p><p>This finding is also confirmed by either 232I or 232T binding with human IgG3 monoclonal antibody (IgG3). That is, the 2D effective affinity and on-rate of 232I binding with IgG3 are about four times higher than those of 232T’s binding (<italic>A</italic><sub>c</sub><italic>K</italic><sub>a</sub>=2.79 ± 0.15×10<sup>-6</sup> and 0.72 ± 0.05×10<sup>-6</sup>μm<sup>4</sup>, respectively; <italic>A</italic><sub>c</sub><italic>k</italic><sub>on</sub>=4.05 ± 0.21 and 0.98 ± 0.07×10<sup>-5</sup>μm<sup>4</sup>s<sup>-1</sup>, respectively), while their binding off-rates are similar (14.53 ± 4.10 and 13.64 ± 5.42 s<sup>-1</sup>, respectively) (Figure 3F-H).</p><p>In summary, we confirm that FcγRIIB-I232T polymorphic change indeed reduces the 2D binding affinity and on-rate of FcγRIIB binding to IgG1, IgG2 and IgG3.</p><disp-quote content-type="editor-comment"><p>4) The authors might want to cite Xu et al. (2008) if they agree it was first to use this effective FRET pair.</p></disp-quote><p>We thank the reviewer for pointing this out and agree with their comment. We have updated our references and cited Xu et al. (2008) in the revised manuscript (Results and Discussion section).</p><disp-quote content-type="editor-comment"><p>5) That authors might want to cite Chesla et al. (2000) to indicate that others have found difficult to explain results after changing membrane anchor and perhaps this phenomenon might be invested in these situations.</p></disp-quote><p>We thank the reviewer for this suggestion. Our current finding, as suggested by the reviewer, may provide a mechanistic insight to explain the results reported in this paper. This paper found that membrane anchor pattern (transmembrane or glycosylphosphatidylinositol) influences the two-dimensional kinetic rate of ligand binding (Chesla et al., 2000). It is proposed that the replacement of polypeptide with GPI anchor potentially result in a conformational change of CD16a, although there is no direct evidence to show such conformational change in that paper per se. Here, combining with molecular dynamics simulations and single-cell FRET assay, we provide the first line evidence to directly reveal that the tilting of the TM domain by I232T polymorphic change induces the orientation of the ectodomain of FcγRIIB towards plasma membrane to allosterically impede ligand recognition. As the reviewer suggested, our finding could potentially explain the experimental phenomenon in the original studies by Chesla et al. We have cited this paper and added related discussion into revised manuscript (Results and Discussion section).</p></body></sub-article></article>